FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2396469618> ?p ?o ?g. }

• W2396469618 endingPage "1362" @default.
• W2396469618 startingPage "1355" @default.
• W2396469618 abstract "Background: The acute myeloid leukemia 1 (AML1)-eight-twenty-one (ETO) fusion protein generated by the t(8;21)(q22;q22) translocation is considered to display a crucial role in leukemogenesis in AML. By focusing on the anti-leukemia effects of eyes absent 4 (EYA4) gene on AML cells, we investigated the biologic and molecular mechanism associated with AML1-ETO expressed in t(8;21) AML. Methods: Qualitative polymerase chain reaction (PCR), quantitative reverse transcription PCR (RT-PCR), and Western blotting analysis were used to observe the mRNA and protein expression levels of EYA4 in cell lines. Different plasmids (including mutant plasmids) of dual luciferase reporter vector were built to study the binding status of AML1-ETO to the promoter region of EYA4. Chromatin immunoprecipitation assay was used to study the epigenetic silencing mechanism of EYA4. Bisulfite sequencing was applied to detect the methylation status in EYA4 promoter region. The influence of EYA4 gene in the cell proliferation, apoptosis, and cell clone-forming ability was detected by the technique of Cell Counting Kit-8, flow cytometry, and clonogenic assay. Results: EYA4 gene was hypermethylated in AML1-ETO+ patients and its expression was down-regulated by 6-fold in Kasumi-1 and SKNO-1 cells, compared to HL-60 and SKNO-1-siA/E cells, respectively. We demonstrated that AML1-ETO triggered the epigenetic silencing of EYA4 gene by binding at AML1-binding sites and recruiting histone deacetylase 1 and DNA methyltransferases. Enhanced EYA4 expression levels inhibited cellular proliferation and suppressed cell colony formation in AML1-ETO+ cell lines. We also found EYA4 transfection increased apoptosis of Kasumi-1 and SKNO-1 cells by 1.6-fold and 1.4-fold compared to negative control, respectively. Conclusions: Our study identified EYA4 gene as targets for AML1-ETO and indicated it as a novel tumor suppressor gene. In addition, we provided evidence that EYA4 gene might be a novel therapeutic target and a potential candidate for treating AML1-ETO+ t (8;21) AML." @default.
• W2396469618 created "2016-06-24" @default.
• W2396469618 creator A5012949929 @default.
• W2396469618 creator A5015458777 @default.
• W2396469618 creator A5024340488 @default.
• W2396469618 creator A5031358820 @default.
• W2396469618 creator A5039496752 @default.
• W2396469618 creator A5041289789 @default.
• W2396469618 creator A5048679350 @default.
• W2396469618 creator A5069718210 @default.
• W2396469618 creator A5076455280 @default.
• W2396469618 creator A5081782440 @default.
• W2396469618 creator A5084819347 @default.
• W2396469618 creator A5089511600 @default.
• W2396469618 date "2016-06-05" @default.
• W2396469618 modified "2023-10-16" @default.
• W2396469618 title "Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia" @default.
• W2396469618 cites W1534965621 @default.
• W2396469618 cites W1558973832 @default.
• W2396469618 cites W1577373236 @default.
• W2396469618 cites W1769017161 @default.
• W2396469618 cites W1917925231 @default.
• W2396469618 cites W1930980342 @default.
• W2396469618 cites W1963554993 @default.
• W2396469618 cites W1971356393 @default.
• W2396469618 cites W1987714872 @default.
• W2396469618 cites W1989952317 @default.
• W2396469618 cites W2008140876 @default.
• W2396469618 cites W2016093629 @default.
• W2396469618 cites W2021236919 @default.
• W2396469618 cites W2030251295 @default.
• W2396469618 cites W2033110588 @default.
• W2396469618 cites W2036717227 @default.
• W2396469618 cites W2038131544 @default.
• W2396469618 cites W2047718660 @default.
• W2396469618 cites W2062749633 @default.
• W2396469618 cites W2068631511 @default.
• W2396469618 cites W2070919286 @default.
• W2396469618 cites W2073632680 @default.
• W2396469618 cites W2079120937 @default.
• W2396469618 cites W2081129244 @default.
• W2396469618 cites W2081633264 @default.
• W2396469618 cites W2096756851 @default.
• W2396469618 cites W2117439162 @default.
• W2396469618 cites W2121742208 @default.
• W2396469618 cites W2127517334 @default.
• W2396469618 cites W2131042290 @default.
• W2396469618 cites W2144395887 @default.
• W2396469618 cites W2150113701 @default.
• W2396469618 cites W2150683921 @default.
• W2396469618 cites W2157439965 @default.
• W2396469618 cites W2272093478 @default.
• W2396469618 doi "https://doi.org/10.4103/0366-6999.182838" @default.
• W2396469618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4894048" @default.
• W2396469618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27231175" @default.
• W2396469618 hasPublicationYear "2016" @default.
• W2396469618 type Work @default.
• W2396469618 sameAs 2396469618 @default.
• W2396469618 citedByCount "5" @default.
• W2396469618 countsByYear W23964696182018 @default.
• W2396469618 countsByYear W23964696182020 @default.
• W2396469618 countsByYear W23964696182022 @default.
• W2396469618 countsByYear W23964696182023 @default.
• W2396469618 crossrefType "journal-article" @default.
• W2396469618 hasAuthorship W2396469618A5012949929 @default.
• W2396469618 hasAuthorship W2396469618A5015458777 @default.
• W2396469618 hasAuthorship W2396469618A5024340488 @default.
• W2396469618 hasAuthorship W2396469618A5031358820 @default.
• W2396469618 hasAuthorship W2396469618A5039496752 @default.
• W2396469618 hasAuthorship W2396469618A5041289789 @default.
• W2396469618 hasAuthorship W2396469618A5048679350 @default.
• W2396469618 hasAuthorship W2396469618A5069718210 @default.
• W2396469618 hasAuthorship W2396469618A5076455280 @default.
• W2396469618 hasAuthorship W2396469618A5081782440 @default.
• W2396469618 hasAuthorship W2396469618A5084819347 @default.
• W2396469618 hasAuthorship W2396469618A5089511600 @default.
• W2396469618 hasBestOaLocation W23964696181 @default.
• W2396469618 hasConcept C101762097 @default.
• W2396469618 hasConcept C104317684 @default.
• W2396469618 hasConcept C119056186 @default.
• W2396469618 hasConcept C134320426 @default.
• W2396469618 hasConcept C150194340 @default.
• W2396469618 hasConcept C153911025 @default.
• W2396469618 hasConcept C190727270 @default.
• W2396469618 hasConcept C2778729363 @default.
• W2396469618 hasConcept C41091548 @default.
• W2396469618 hasConcept C502942594 @default.
• W2396469618 hasConcept C54355233 @default.
• W2396469618 hasConcept C62112901 @default.
• W2396469618 hasConcept C86803240 @default.
• W2396469618 hasConceptScore W2396469618C101762097 @default.
• W2396469618 hasConceptScore W2396469618C104317684 @default.
• W2396469618 hasConceptScore W2396469618C119056186 @default.
• W2396469618 hasConceptScore W2396469618C134320426 @default.
• W2396469618 hasConceptScore W2396469618C150194340 @default.
• W2396469618 hasConceptScore W2396469618C153911025 @default.
• W2396469618 hasConceptScore W2396469618C190727270 @default.
• W2396469618 hasConceptScore W2396469618C2778729363 @default.

• next